On this episode of our award-winning podcast, Tom continues his discussion with two leading pharmacy experts on what medications and classes of medications are in expedited approval and what this means for patients in overall efficacy and safety, the benefits and the drawbacks.
Moderator:Tomas Villanueva, DO, MBA, FACPE, SFHMSenior Principal, Clinical Operations and QualityVizient
Guests:Jeni Hayes, PharmD, MSPharm, BCPSSenior Clinical Manager, Pharmacy OutcomesCenter for Pharmacy Practice Excellence
On this episode of our award-winning podcast, Tom continues his discussion with two leading pharmacy experts on what medications and classes of medications are in expedited approval and what this means for patients in overall efficacy and safety, the benefits and the drawbacks.
Moderator:
Tomas Villanueva, DO, MBA, FACPE, SFHM
Senior Principal, Clinical Operations and Quality
Vizient
Guests:
Jeni Hayes, PharmD, MSPharm, BCPS
Senior Clinical Manager, Pharmacy Outcomes
Center for Pharmacy Practice Excellence
Vizient
Steven Lucio, PharmD, BCPS
Senior Principal, Pharmacy Solutions
Center for Pharmacy Practice Excellence
Vizient
Show Notes:
[00:44] Recap of approval pathways
[01:33] Examples of accelerated approval drugs and effect of delays
[03:59] Only 50 percent of accelerated approvals converted to full approval
[05:32] Challenge in keeping track of drugs in the process
[06:13] Huge cost of ineffective drugs that win approval
[07:02] Huge cost of developing drugs that end up not working
[09:55] Need for providers to look at evidence on approved drugs
Links | Resources:
To contact Modern Practice: modernpracticepodcast@vizientinc.com
Steven’s email: steven.lucio@vizientinc.com
Jeni’s email: jeni.hayes@vizientinc.com
FDA’s accelerated approval update page: Click here
Vizient Pharmacy Market Highlights – Dec. 2022: PMO322_PharmacyMarketOutlook_Highlights.pdf
Subscribe Today!
Apple Podcasts
Amazon Podcasts
Android
Google Podcasts
Spotify
Stitcher
RSS Feed
View more
